Jeffrey Bertolini, the Chief Operating Officer of Carlsmed, Inc., has reported a series of stock transactions that reflect his ongoing management of personal holdings in the company. These transactions, filed with the SEC on October 6, 2026, are significant as they may influence perceptions of the company's stability and executive confidence.
Background
Carlsmed, Inc. operates within the surgical and medical instruments and apparatus sector. The company is listed under the Central Index Key (CIK) 0001794546. Recent filings indicate that Bertolini has been actively managing his stock portfolio, with multiple transactions occurring in early October 2026.
What the Filing Says
The SEC filing details two significant transactions on October 5, 2026. Bertolini acquired 747 shares of common stock at a price of $5.915 per share and sold 747 shares at a price of $14.39 per share. Following these transactions, he owns a total of 22,489 shares. Additionally, he exercised stock options for 747 shares, which were granted at an exercise price of $5.915.
Impact
These transactions may affect various stakeholders, including investors, analysts, and competitors within the surgical and medical instruments industry. The reported sales were executed under a Rule 10b5-1 trading plan, indicating a pre-determined strategy for managing stock sales. This could provide insights into Bertolini's confidence in the company's future performance.
What's Next
The filing does not say what happens next.
Read Next
Lee Chae Increases Stake in Magnachip Semiconductor Corp
Jamie Odell Reports Major Stock Transactions with Light & Wonder
Guiheen Lawrence P. Acquires 10,000 Shares of ADMA Biologics
Gilliam Joseph E reports significant stock transactions
ADMA Biologics CEO Grossman Reports Major Stock Transactions
Saba Capital Management reveals stock acquisitions in SEC filing









